656 related articles for article (PubMed ID: 27836911)
1. Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53.
Pfister NT; Prives C
Cold Spring Harb Perspect Med; 2017 Feb; 7(2):. PubMed ID: 27836911
[TBL] [Abstract][Full Text] [Related]
2. Friend or Foe: MicroRNAs in the p53 network.
Luo Z; Cui R; Tili E; Croce C
Cancer Lett; 2018 Apr; 419():96-102. PubMed ID: 29330109
[TBL] [Abstract][Full Text] [Related]
3. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
4. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
5. [Advances on mutant p53 research].
Li DH; Zhang LQ; He FC
Yi Chuan; 2008 Jun; 30(6):697-703. PubMed ID: 18550490
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional activities of mutant p53: when mutations are more than a loss.
Kim E; Deppert W
J Cell Biochem; 2004 Nov; 93(5):878-86. PubMed ID: 15449312
[TBL] [Abstract][Full Text] [Related]
7. Transcription regulation by mutant p53.
Weisz L; Oren M; Rotter V
Oncogene; 2007 Apr; 26(15):2202-11. PubMed ID: 17401429
[TBL] [Abstract][Full Text] [Related]
8. Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome.
Neilsen PM; Noll JE; Suetani RJ; Schulz RB; Al-Ejeh F; Evdokiou A; Lane DP; Callen DF
Oncotarget; 2011 Dec; 2(12):1203-17. PubMed ID: 22203497
[TBL] [Abstract][Full Text] [Related]
9. New therapeutic strategies to treat human cancers expressing mutant p53 proteins.
Blandino G; Di Agostino S
J Exp Clin Cancer Res; 2018 Feb; 37(1):30. PubMed ID: 29448954
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
Sigal A; Rotter V
Cancer Res; 2000 Dec; 60(24):6788-93. PubMed ID: 11156366
[TBL] [Abstract][Full Text] [Related]
11. Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53.
Abarzúa P; LoSardo JE; Gubler ML; Neri A
Cancer Res; 1995 Aug; 55(16):3490-4. PubMed ID: 7627952
[TBL] [Abstract][Full Text] [Related]
12. Mutant p53 and mTOR/PKM2 regulation in cancer cells.
Dando I; Cordani M; Donadelli M
IUBMB Life; 2016 Sep; 68(9):722-6. PubMed ID: 27385486
[TBL] [Abstract][Full Text] [Related]
13. Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes.
Scian MJ; Stagliano KE; Deb D; Ellis MA; Carchman EH; Das A; Valerie K; Deb SP; Deb S
Oncogene; 2004 May; 23(25):4430-43. PubMed ID: 15077194
[TBL] [Abstract][Full Text] [Related]
14. SMARCD1 is a transcriptional target of specific non-hotspot mutant p53 forms.
Adduri RSR; George SA; Kavadipula P; Bashyam MD
J Cell Physiol; 2020 May; 235(5):4559-4570. PubMed ID: 31637714
[TBL] [Abstract][Full Text] [Related]
15. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.
Petitjean A; Mathe E; Kato S; Ishioka C; Tavtigian SV; Hainaut P; Olivier M
Hum Mutat; 2007 Jun; 28(6):622-9. PubMed ID: 17311302
[TBL] [Abstract][Full Text] [Related]
16. The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library.
Kawaguchi T; Kato S; Otsuka K; Watanabe G; Kumabe T; Tominaga T; Yoshimoto T; Ishioka C
Oncogene; 2005 Oct; 24(46):6976-81. PubMed ID: 16007150
[TBL] [Abstract][Full Text] [Related]
17. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
Willis A; Jung EJ; Wakefield T; Chen X
Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206
[TBL] [Abstract][Full Text] [Related]
18. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
[TBL] [Abstract][Full Text] [Related]
19. Mutant p53 proteins behave in a dominant, negative fashion in vivo.
Hachiya M; Chumakov A; Miller CW; Akashi M; Said J; Koeffler HP
Anticancer Res; 1994; 14(5A):1853-9. PubMed ID: 7847818
[TBL] [Abstract][Full Text] [Related]
20. The oncogenic roles of p53 mutants in mouse models.
Lozano G
Curr Opin Genet Dev; 2007 Feb; 17(1):66-70. PubMed ID: 17208429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
